Skip to main content
OSTI.GOVU.S. Department of Energy Office of Scientific and Technical Information
U.S. Department of Energy
Office of Scientific and Technical Information
 

Preparatory clinical studies of Pi-mesons at TRIUMF

Journal Article · · Radiat. Res., Suppl.; (United States)
DOI:https://doi.org/10.2307/3583538· OSTI ID:5203595
; ; ; ; ; ;
Eighty patients have been treated with Pi-mesons (pions) at TRIUMF between 1979-1984. The patients had tumors rarely curable by standard methods and had no prior radiotherapy. The distribution by site included skin, metastatic nodules (13), brain, glioblastoma multiforme (32), pelvis, rectosigmoid (15), prostate (12), bladder (7), and ovary (1). The studies involve serial escalations of pion dose until maximum tissue tolerance is reached, monitoring the response at each dose increment. Sites were chosen for study where lack of local control is a significant cause of treatment failure with conventional radiation therapy. The low dose rate and the available beam access at TRIUMF limit the number of patients treated and the volume treatable. A 3-D treatment planning program is in use, and a 3-D display of the dose distribution delivered in brain tumor treatments has been developed using the PET scanner. In practice, new methods introduced for measurement of tissue response include tumor growth delay curves, fine-needle biopsy mapping, and PET scanning of brain tumors. The use of endoscopic assessment of the rectosigmoid region is emphasized. Treatment results of glioblastoma multiforme show that the median survival for patients treated to 125 pion cGy/fx is in the range of 187-198 days; for patients receiving 170 cGy per dose/fraction (fx) the range is 290-315 days, and for those receiving 200-220 cGy/fx the median survival is in excess of 290 days. For pelvic malignancies the local control obtained with doses of 2500 cGy or less was 50% in 12 asable patients; it was 75% in 20 patients who had 3000 cGy or more.
Research Organization:
Cancer Control Agency of British Columbia, Vancouver
OSTI ID:
5203595
Journal Information:
Radiat. Res., Suppl.; (United States), Journal Name: Radiat. Res., Suppl.; (United States); ISSN RARSA
Country of Publication:
United States
Language:
English

Similar Records

[F-18]-fluorodeoxyglucose positron emission tomography for targeting radiation dose escalation for patients with glioblastoma multiforme: Clinical outcomes and patterns of failure
Journal Article · Tue Feb 28 23:00:00 EST 2006 · International Journal of Radiation Oncology, Biology and Physics · OSTI ID:20793360
Halogenated pyrimidines as radiosensitizers in the treatment of glioblastoma multiforme
Journal Article · Thu Oct 01 00:00:00 EDT 1987 · Am. J. Clin. Oncol.; (United States) · OSTI ID:5849649
Prognostic Value of Early [{sup 18}F]Fluoroethyltyrosine Positron Emission Tomography After Radiochemotherapy in Glioblastoma Multiforme
Journal Article · Sun May 01 00:00:00 EDT 2011 · International Journal of Radiation Oncology, Biology and Physics · OSTI ID:21491733

Related Subjects

550603 -- Medicine-- External Radiation in Therapy-- (1980-)
560151* -- Radiation Effects on Animals-- Man
62 RADIOLOGY AND NUCLEAR MEDICINE
63 RADIATION, THERMAL, AND OTHER ENVIRON. POLLUTANT EFFECTS ON LIVING ORGS. AND BIOL. MAT.
BEAMS
BLADDER
BODY
BRAIN
CENTRAL NERVOUS SYSTEM
DISEASES
DOSE-RESPONSE RELATIONSHIPS
DOSES
FEMALE GENITALS
GLANDS
GONADS
MALE GENITALS
MEDICINE
MESON BEAMS
NEOPLASMS
NERVOUS SYSTEM
NUCLEAR MEDICINE
ORGANS
OVARIES
PARTICLE BEAMS
PATIENTS
PION BEAMS
PROSTATE
RADIATION DOSES
RADIOLOGY
RADIOTHERAPY
SKIN
THERAPY
URINARY TRACT